Selective activity over a constitutively active RET‐variant of the oral multikinase inhibitor dovitinib: Results of the CNIO‐BR002 phase I‐trial

BACKGROUND: Given our preclinical data showing synergy between dovitinib and paclitaxel in preclinical models we conducted this phase I trial aiming to define the recommended phase II‐dose (RP2D) on the basis of toxicity and pharmacodynamic criteria while searching for genetic variants that could se...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Quintela-Fandino, Miguel, Bueno, Maria J., Lombardia, Luis, Gil, Marta, Gonzalez-Martin, Antonio, Marquez, Raul, Bratos, Raquel, Guerra, Juan, Tan, Eugene, Lopez, Antonio, Colomer, Ramon, Salazar, Ramon
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2014
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528587/
https://ncbi.nlm.nih.gov/pubmed/25103625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.07.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados